Peptides and chemical compound for inhibition of SHP2 function

Details Peptides and chemical compound for inhibition of SHP2 function Peptides and chemical compound for inhibition of SHP2 function

2006-07-03

2009-06-16

Blanchard, David J. (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

4 to 5 amino acid residues in defined sequence

C530S300000, C530S331000, C530S345000

Reexamination Certificate

active

07547760

ABSTRACT:
The present invention relates to the inhibition of the function of SHP2 by both anti-SHP2 peptides and the chemical compound 4-(2-sulfaminoethyl)benzoic acid, SEBA, and SEBA derivatives binding to the phosphotyrosyl phosphatase domain of SHP2 thereby inhibiting the function of SHP2 both in vitro and in vivo. In addition, the inhibition of SHP2 may be useful as a treatment for human disease, and it has been shown that interfering with SHP2 function using the anti-SHP2 peptides and SEBA compounds reverses cell transformation and induces remission of preformed tumors in vivo demonstrating a possible treatment for cancer.

REFERENCES:
patent: 6200807 (2001-03-01), Bennett et al.
patent: 6270981 (2001-08-01), Carpenter et al.
patent: 6756478 (2004-06-01), Valladeau et al.
patent: 6849420 (2005-02-01), Vanhasebroeck et al.
patent: 7026283 (2006-04-01), Fleming et al.
patent: 2004/0265910 (2004-12-01), Haaland et al.
patent: WO2004020466 (2004-03-01), None
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activites by site-directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, E., Watanabe, S., Dalton, S., and Sporn, M.B. Transforming growth factor a: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8 No. 3, pp. 1247-1252.
Schwartz, G.P., Burke, G.T., and Katsoyannis, P.G. A superactive insulin: [B10-aspartic acid]insulin (human). Proceedings of the National Acacdemy of Sciences, 1987. vol. 84, pp. 6408-6411.
Lin, M.C., Wright, D.E., Hruby, V.J., and Rodbell, M. Structure-function relationships in glucagon: properties of highly purified Des-His1-, Monoiodo-, and [Des-Asn28, Thr29](homoserine lactone27)-glucagon. Biochemistry, 1975. vol. 14, No. 8, pp. 1559-1563.
Qin, C., Wavreille, A., and Pei, D. Alternative mode of binding to phosphotyrosyl peptides by Src Homology-2 domains. Biochemistry, 2005. vol. 44, pp. 12196-12202.
Imhof, D., Wavreille, A., May, A., Zacharias, M., Tridandapani, S., and Pei, D. Sequence specficity of SHP1 and SHP2 Src homology 2 domains. Journal of Biological Chemistry, 2006. vol. 281 No. 29, pp. 20271-20282.
Lesuisse, Lange, Deprez, Benard, Schoot, Delettre, Marquette, Broto, Jean-Baptiste, Bichet, Sarubbi, and Mandine. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. Journal of Medicinal Chemistry, 2002. vol. 45, pp. 2379-2387.

Affiliated with

Also associated with

Rating

Peptides and chemical compound for inhibition of SHP2 function does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides and chemical compound for inhibition of SHP2 function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides and chemical compound for inhibition of SHP2 function will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4092973